NO323236B1 - Indolderivater, deres anvendelse og farmasoytiske sammensetninger omfattende disse - Google Patents
Indolderivater, deres anvendelse og farmasoytiske sammensetninger omfattende disse Download PDFInfo
- Publication number
- NO323236B1 NO323236B1 NO20026005A NO20026005A NO323236B1 NO 323236 B1 NO323236 B1 NO 323236B1 NO 20026005 A NO20026005 A NO 20026005A NO 20026005 A NO20026005 A NO 20026005A NO 323236 B1 NO323236 B1 NO 323236B1
- Authority
- NO
- Norway
- Prior art keywords
- dihydro
- indole
- piperidin
- fluoro
- quinolin
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 6
- 150000002475 indoles Chemical class 0.000 title claims description 3
- 229940054051 antipsychotic indole derivative Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 112
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 46
- 230000000694 effects Effects 0.000 claims description 20
- 238000011282 treatment Methods 0.000 claims description 18
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 201000000980 schizophrenia Diseases 0.000 claims description 11
- 208000024891 symptom Diseases 0.000 claims description 11
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 208000028017 Psychotic disease Diseases 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 5
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 5
- 208000019695 Migraine disease Diseases 0.000 claims description 5
- 239000000164 antipsychotic agent Substances 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 206010027599 migraine Diseases 0.000 claims description 5
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 208000011688 Generalised anxiety disease Diseases 0.000 claims description 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 3
- 230000016571 aggressive behavior Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 208000029364 generalized anxiety disease Diseases 0.000 claims description 3
- 208000019906 panic disease Diseases 0.000 claims description 3
- 230000007958 sleep Effects 0.000 claims description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- FAYLLIQOZYADJB-UHFFFAOYSA-N 1-(3,4-dihydro-2h-quinolin-1-yl)-4-[4-(4-fluoro-1h-indol-3-yl)piperidin-1-yl]butan-1-one Chemical compound C1CCC2=CC=CC=C2N1C(=O)CCCN(CC1)CCC1C1=CNC2=C1C(F)=CC=C2 FAYLLIQOZYADJB-UHFFFAOYSA-N 0.000 claims description 2
- CKHXYJHHWFPINQ-UHFFFAOYSA-N 4-[4-(5-chloro-1h-indol-3-yl)piperidin-1-yl]-1-(3,4-dihydro-2h-quinolin-1-yl)butan-1-one Chemical compound C1CCC2=CC=CC=C2N1C(=O)CCCN(CC1)CCC1C1=CNC2=CC=C(Cl)C=C21 CKHXYJHHWFPINQ-UHFFFAOYSA-N 0.000 claims description 2
- AXZHMCJZZKXAGI-UHFFFAOYSA-N 4-[4-(7-chloro-1h-indol-3-yl)piperidin-1-yl]-1-(3,4-dihydro-2h-quinolin-1-yl)butan-1-one Chemical compound C1CCC2=CC=CC=C2N1C(=O)CCCN(CC1)CCC1C1=CNC2=C1C=CC=C2Cl AXZHMCJZZKXAGI-UHFFFAOYSA-N 0.000 claims description 2
- SHOFJJYJPCUKIL-UHFFFAOYSA-N 4-[4-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]butyl]-1,4-benzoxazin-3-one Chemical compound O=C1COC2=CC=CC=C2N1CCCCN(CC1)CCC1C1=CNC2=CC=C(F)C=C21 SHOFJJYJPCUKIL-UHFFFAOYSA-N 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- JJCXSTPQHBGFFN-UHFFFAOYSA-N 1-(3,4-dihydro-1h-isoquinolin-2-yl)-3-[4-(4-fluoro-1h-indol-3-yl)piperidin-1-yl]propan-1-one Chemical compound C1CC2=CC=CC=C2CN1C(=O)CCN(CC1)CCC1C1=CNC2=C1C(F)=CC=C2 JJCXSTPQHBGFFN-UHFFFAOYSA-N 0.000 claims 1
- LBQPBGAWOICMMY-UHFFFAOYSA-N 1-(3,4-dihydro-1h-isoquinolin-2-yl)-3-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]propan-1-one Chemical compound C1CC2=CC=CC=C2CN1C(=O)CCN(CC1)CCC1C1=CNC2=CC=C(F)C=C21 LBQPBGAWOICMMY-UHFFFAOYSA-N 0.000 claims 1
- QKDAJRUPDKYNRO-UHFFFAOYSA-N 1-(3,4-dihydro-1h-isoquinolin-2-yl)-4-[4-(4-fluoro-1h-indol-3-yl)piperidin-1-yl]butan-1-one Chemical compound C1CC2=CC=CC=C2CN1C(=O)CCCN(CC1)CCC1C1=CNC2=C1C(F)=CC=C2 QKDAJRUPDKYNRO-UHFFFAOYSA-N 0.000 claims 1
- UOPZVMQSXQGJPX-UHFFFAOYSA-N 1-(3,4-dihydro-1h-isoquinolin-2-yl)-4-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]butan-1-one Chemical compound C1CC2=CC=CC=C2CN1C(=O)CCCN(CC1)CCC1C1=CNC2=CC=C(F)C=C21 UOPZVMQSXQGJPX-UHFFFAOYSA-N 0.000 claims 1
- WNPFFSLNMCAVDB-UHFFFAOYSA-N 1-(3,4-dihydro-1h-isoquinolin-2-yl)-5-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]pentan-1-one Chemical compound C1CC2=CC=CC=C2CN1C(=O)CCCCN(CC1)CCC1C1=CNC2=CC=C(F)C=C21 WNPFFSLNMCAVDB-UHFFFAOYSA-N 0.000 claims 1
- LDOQLNGSOSRYMH-UHFFFAOYSA-N 1-(3,4-dihydro-1h-isoquinolin-2-yl)-6-[4-(4-fluoro-1h-indol-3-yl)piperidin-1-yl]hexan-1-one Chemical compound C1CC2=CC=CC=C2CN1C(=O)CCCCCN(CC1)CCC1C1=CNC2=C1C(F)=CC=C2 LDOQLNGSOSRYMH-UHFFFAOYSA-N 0.000 claims 1
- LUHSGVLLJASOCH-UHFFFAOYSA-N 1-(3,4-dihydro-1h-isoquinolin-2-yl)-6-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]hexan-1-one Chemical compound C1CC2=CC=CC=C2CN1C(=O)CCCCCN(CC1)CCC1C1=CNC2=CC=C(F)C=C21 LUHSGVLLJASOCH-UHFFFAOYSA-N 0.000 claims 1
- QZYUOQVZPMMHRN-UHFFFAOYSA-N 1-(3,4-dihydro-2h-quinolin-1-yl)-3-[4-(4-fluoro-1h-indol-3-yl)piperidin-1-yl]propan-1-one Chemical compound C1CCC2=CC=CC=C2N1C(=O)CCN(CC1)CCC1C1=CNC2=C1C(F)=CC=C2 QZYUOQVZPMMHRN-UHFFFAOYSA-N 0.000 claims 1
- NMDUEZSJYPLVLS-UHFFFAOYSA-N 1-(3,4-dihydro-2h-quinolin-1-yl)-3-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]propan-1-one Chemical compound C1CCC2=CC=CC=C2N1C(=O)CCN(CC1)CCC1C1=CNC2=CC=C(F)C=C21 NMDUEZSJYPLVLS-UHFFFAOYSA-N 0.000 claims 1
- ARBGPUGFFUMXCU-UHFFFAOYSA-N 1-(3,4-dihydro-2h-quinolin-1-yl)-4-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]butan-1-one Chemical compound C1CCC2=CC=CC=C2N1C(=O)CCCN(CC1)CCC1C1=CNC2=CC=C(F)C=C21 ARBGPUGFFUMXCU-UHFFFAOYSA-N 0.000 claims 1
- WAORUEOHHLGTDP-UHFFFAOYSA-N 1-(3,4-dihydro-2h-quinolin-1-yl)-5-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]pentan-1-one Chemical compound C1CCC2=CC=CC=C2N1C(=O)CCCCN(CC1)CCC1C1=CNC2=CC=C(F)C=C21 WAORUEOHHLGTDP-UHFFFAOYSA-N 0.000 claims 1
- RRJSVTKIKRWIOS-UHFFFAOYSA-N 1-(3,4-dihydro-2h-quinolin-1-yl)-6-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]hexan-1-one Chemical compound C1CCC2=CC=CC=C2N1C(=O)CCCCCN(CC1)CCC1C1=CNC2=CC=C(F)C=C21 RRJSVTKIKRWIOS-UHFFFAOYSA-N 0.000 claims 1
- JFSOFXZDECSVCC-UHFFFAOYSA-N 1-[3-[4-(5-chloro-1h-indol-3-yl)piperidin-1-yl]propyl]-3,4-dihydroquinolin-2-one Chemical compound O=C1CCC2=CC=CC=C2N1CCCN(CC1)CCC1C1=CNC2=CC=C(Cl)C=C21 JFSOFXZDECSVCC-UHFFFAOYSA-N 0.000 claims 1
- USLDVLHOXAMFMO-UHFFFAOYSA-N 1-[3-[4-(5-fluoro-1-methylindol-3-yl)piperidin-1-yl]propyl]-3,4-dihydroquinolin-2-one Chemical compound C12=CC(F)=CC=C2N(C)C=C1C1CCN(CCCN2C3=CC=CC=C3CCC2=O)CC1 USLDVLHOXAMFMO-UHFFFAOYSA-N 0.000 claims 1
- YVGSMROAIJJFKF-UHFFFAOYSA-N 1-[3-[4-(5-fluoro-1h-indol-3-yl)-3,6-dihydro-2h-pyridin-1-yl]propyl]-3,4-dihydroquinolin-2-one Chemical compound O=C1CCC2=CC=CC=C2N1CCCN(CC1)CC=C1C1=CNC2=CC=C(F)C=C21 YVGSMROAIJJFKF-UHFFFAOYSA-N 0.000 claims 1
- BIEFXJWOCNALSB-UHFFFAOYSA-N 1-[3-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]propyl]-3,4-dihydroquinolin-2-one Chemical compound O=C1CCC2=CC=CC=C2N1CCCN(CC1)CCC1C1=CNC2=CC=C(F)C=C21 BIEFXJWOCNALSB-UHFFFAOYSA-N 0.000 claims 1
- NRQZICHWSLTRGD-UHFFFAOYSA-N 1-[4-[4-(1-butyl-5-fluoroindol-3-yl)-3,6-dihydro-2h-pyridin-1-yl]butyl]-3,4-dihydroquinolin-2-one Chemical compound C12=CC(F)=CC=C2N(CCCC)C=C1C(CC1)=CCN1CCCCN1C2=CC=CC=C2CCC1=O NRQZICHWSLTRGD-UHFFFAOYSA-N 0.000 claims 1
- HJLGCUAUOHAPAQ-UHFFFAOYSA-N 1-[4-[4-(5-chloro-1h-indol-3-yl)piperidin-1-yl]butyl]-3,4-dihydroquinolin-2-one Chemical compound O=C1CCC2=CC=CC=C2N1CCCCN(CC1)CCC1C1=CNC2=CC=C(Cl)C=C21 HJLGCUAUOHAPAQ-UHFFFAOYSA-N 0.000 claims 1
- QPMIEPFWIVUMBK-UHFFFAOYSA-N 1-[4-[4-(5-fluoro-1-methylindol-3-yl)piperidin-1-yl]butyl]-3,4-dihydroquinolin-2-one Chemical compound C12=CC(F)=CC=C2N(C)C=C1C1CCN(CCCCN2C3=CC=CC=C3CCC2=O)CC1 QPMIEPFWIVUMBK-UHFFFAOYSA-N 0.000 claims 1
- SWSVBXDGTNXZPC-UHFFFAOYSA-N 1-[4-[4-(5-fluoro-1h-indol-3-yl)-3,6-dihydro-2h-pyridin-1-yl]butyl]-3,4-dihydroquinolin-2-one Chemical compound O=C1CCC2=CC=CC=C2N1CCCCN(CC1)CC=C1C1=CNC2=CC=C(F)C=C21 SWSVBXDGTNXZPC-UHFFFAOYSA-N 0.000 claims 1
- PWJRYZJSQMCNJJ-UHFFFAOYSA-N 1-[4-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]butyl]-3,4-dihydroquinolin-2-one Chemical compound O=C1CCC2=CC=CC=C2N1CCCCN(CC1)CCC1C1=CNC2=CC=C(F)C=C21 PWJRYZJSQMCNJJ-UHFFFAOYSA-N 0.000 claims 1
- ILMUUVQSBQQPBD-UHFFFAOYSA-N 1-[4-[4-(7-chloro-1h-indol-3-yl)piperidin-1-yl]butyl]-3,4-dihydroquinolin-2-one Chemical compound O=C1CCC2=CC=CC=C2N1CCCCN(CC1)CCC1C1=CNC2=C1C=CC=C2Cl ILMUUVQSBQQPBD-UHFFFAOYSA-N 0.000 claims 1
- ZJBBTQFOJMVWDB-UHFFFAOYSA-N 1-[5-[4-(5-chloro-1h-indol-3-yl)piperidin-1-yl]pentyl]-3,4-dihydroquinolin-2-one Chemical compound O=C1CCC2=CC=CC=C2N1CCCCCN(CC1)CCC1C1=CNC2=CC=C(Cl)C=C21 ZJBBTQFOJMVWDB-UHFFFAOYSA-N 0.000 claims 1
- LNAFMHHJHKNUAC-UHFFFAOYSA-N 1-[5-[4-(5-fluoro-1h-indol-3-yl)-3,6-dihydro-2h-pyridin-1-yl]pentyl]-3,4-dihydroquinolin-2-one Chemical compound O=C1CCC2=CC=CC=C2N1CCCCCN(CC1)CC=C1C1=CNC2=CC=C(F)C=C21 LNAFMHHJHKNUAC-UHFFFAOYSA-N 0.000 claims 1
- XAZWSJSZMZAVNA-UHFFFAOYSA-N 1-[5-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]pentyl]-3,4-dihydroquinolin-2-one Chemical compound O=C1CCC2=CC=CC=C2N1CCCCCN(CC1)CCC1C1=CNC2=CC=C(F)C=C21 XAZWSJSZMZAVNA-UHFFFAOYSA-N 0.000 claims 1
- YSXXVIWWPQMSPQ-UHFFFAOYSA-N 2-[4-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]butyl]-3,4-dihydro-1h-isoquinoline Chemical compound C1CC2=CC=CC=C2CN1CCCCN(CC1)CCC1C1=CNC2=CC=C(F)C=C21 YSXXVIWWPQMSPQ-UHFFFAOYSA-N 0.000 claims 1
- HUQHAINPSXMQMX-UHFFFAOYSA-N 2-[4-[4-(5-fluoro-1h-indol-3-yl)piperidin-1-yl]butyl]-6,7-dimethoxy-3,4-dihydro-1h-isoquinoline Chemical compound C1=C(F)C=C2C(C3CCN(CC3)CCCCN3CCC=4C=C(C(=CC=4C3)OC)OC)=CNC2=C1 HUQHAINPSXMQMX-UHFFFAOYSA-N 0.000 claims 1
- DTGIJYDRUHBWMP-UHFFFAOYSA-N 3-[4-(4-chloro-1h-indol-3-yl)piperidin-1-yl]-1-(3,4-dihydro-2h-quinolin-1-yl)propan-1-one Chemical compound C1CCC2=CC=CC=C2N1C(=O)CCN(CC1)CCC1C1=CNC2=C1C(Cl)=CC=C2 DTGIJYDRUHBWMP-UHFFFAOYSA-N 0.000 claims 1
- QKDMDGZXIUXWBZ-UHFFFAOYSA-N 3-[4-(6-chloro-1h-indol-3-yl)piperidin-1-yl]-1-(3,4-dihydro-1h-isoquinolin-2-yl)propan-1-one Chemical compound C1CC2=CC=CC=C2CN1C(=O)CCN(CC1)CCC1C1=CNC2=CC(Cl)=CC=C21 QKDMDGZXIUXWBZ-UHFFFAOYSA-N 0.000 claims 1
- PZDOMLKKERZYJE-UHFFFAOYSA-N 3-[4-(6-chloro-1h-indol-3-yl)piperidin-1-yl]-1-(3,4-dihydro-2h-quinolin-1-yl)propan-1-one Chemical compound C1CCC2=CC=CC=C2N1C(=O)CCN(CC1)CCC1C1=CNC2=CC(Cl)=CC=C21 PZDOMLKKERZYJE-UHFFFAOYSA-N 0.000 claims 1
- LTPAOSMHCBQRKJ-UHFFFAOYSA-N 3-[4-(7-chloro-1h-indol-3-yl)piperidin-1-yl]-1-(3,4-dihydro-1h-isoquinolin-2-yl)propan-1-one Chemical compound C1CC2=CC=CC=C2CN1C(=O)CCN(CC1)CCC1C1=CNC2=C1C=CC=C2Cl LTPAOSMHCBQRKJ-UHFFFAOYSA-N 0.000 claims 1
- JFDARMCVWXUFNF-UHFFFAOYSA-N 4-[4-(4-chloro-1h-indol-3-yl)piperidin-1-yl]-1-(3,4-dihydro-1h-isoquinolin-2-yl)butan-1-one Chemical compound C1CC2=CC=CC=C2CN1C(=O)CCCN(CC1)CCC1C1=CNC2=C1C(Cl)=CC=C2 JFDARMCVWXUFNF-UHFFFAOYSA-N 0.000 claims 1
- PJGVFVZTZLWKLL-UHFFFAOYSA-N 4-[4-(4-chloro-1h-indol-3-yl)piperidin-1-yl]-1-(3,4-dihydro-2h-quinolin-1-yl)butan-1-one Chemical compound C1CCC2=CC=CC=C2N1C(=O)CCCN(CC1)CCC1C1=CNC2=C1C(Cl)=CC=C2 PJGVFVZTZLWKLL-UHFFFAOYSA-N 0.000 claims 1
- XSUIPYMIAKLCLJ-UHFFFAOYSA-N 4-[4-(5-chloro-1h-indol-3-yl)piperidin-1-yl]-1-(3,4-dihydro-1h-isoquinolin-2-yl)butan-1-one Chemical compound C1CC2=CC=CC=C2CN1C(=O)CCCN(CC1)CCC1C1=CNC2=CC=C(Cl)C=C21 XSUIPYMIAKLCLJ-UHFFFAOYSA-N 0.000 claims 1
- CRQWPFRIWMQTIJ-UHFFFAOYSA-N 4-[4-(7-chloro-1h-indol-3-yl)piperidin-1-yl]-1-(3,4-dihydro-1h-isoquinolin-2-yl)butan-1-one Chemical compound C1CC2=CC=CC=C2CN1C(=O)CCCN(CC1)CCC1C1=CNC2=C1C=CC=C2Cl CRQWPFRIWMQTIJ-UHFFFAOYSA-N 0.000 claims 1
- TVOONGKHORGSQM-UHFFFAOYSA-N 4-[4-[4-(5-chloro-1h-indol-3-yl)piperidin-1-yl]butyl]-1,4-benzoxazin-3-one Chemical compound O=C1COC2=CC=CC=C2N1CCCCN(CC1)CCC1C1=CNC2=CC=C(Cl)C=C21 TVOONGKHORGSQM-UHFFFAOYSA-N 0.000 claims 1
- GNCGVLGBCPTOTF-UHFFFAOYSA-N 5-[4-(7-chloro-1h-indol-3-yl)piperidin-1-yl]-1-(3,4-dihydro-1h-isoquinolin-2-yl)pentan-1-one Chemical compound C1CC2=CC=CC=C2CN1C(=O)CCCCN(CC1)CCC1C1=CNC2=C1C=CC=C2Cl GNCGVLGBCPTOTF-UHFFFAOYSA-N 0.000 claims 1
- IVHUOLWHRBOINU-UHFFFAOYSA-N 5-[4-(7-chloro-1h-indol-3-yl)piperidin-1-yl]-1-(3,4-dihydro-2h-quinolin-1-yl)pentan-1-one Chemical compound C1CCC2=CC=CC=C2N1C(=O)CCCCN(CC1)CCC1C1=CNC2=C1C=CC=C2Cl IVHUOLWHRBOINU-UHFFFAOYSA-N 0.000 claims 1
- DZSNYMYDDZROGQ-UHFFFAOYSA-N 6-[4-(4-chloro-1h-indol-3-yl)piperidin-1-yl]-1-(3,4-dihydro-1h-isoquinolin-2-yl)hexan-1-one Chemical compound C1CC2=CC=CC=C2CN1C(=O)CCCCCN(CC1)CCC1C1=CNC2=C1C(Cl)=CC=C2 DZSNYMYDDZROGQ-UHFFFAOYSA-N 0.000 claims 1
- ODHMYIDYPGYCHB-UHFFFAOYSA-N 6-[4-(6-chloro-1h-indol-3-yl)piperidin-1-yl]-1-(3,4-dihydro-1h-isoquinolin-2-yl)hexan-1-one Chemical compound C1CC2=CC=CC=C2CN1C(=O)CCCCCN(CC1)CCC1C1=CNC2=CC(Cl)=CC=C21 ODHMYIDYPGYCHB-UHFFFAOYSA-N 0.000 claims 1
- XABCMPPQBGMSSE-UHFFFAOYSA-N 6-[4-(6-chloro-1h-indol-3-yl)piperidin-1-yl]-1-(3,4-dihydro-2h-quinolin-1-yl)hexan-1-one Chemical compound C1CCC2=CC=CC=C2N1C(=O)CCCCCN(CC1)CCC1C1=CNC2=CC(Cl)=CC=C21 XABCMPPQBGMSSE-UHFFFAOYSA-N 0.000 claims 1
- IQYUCUOHMQQYTE-UHFFFAOYSA-N 6-[4-(7-chloro-1h-indol-3-yl)piperidin-1-yl]-1-(3,4-dihydro-1h-isoquinolin-2-yl)hexan-1-one Chemical compound C1CC2=CC=CC=C2CN1C(=O)CCCCCN(CC1)CCC1C1=CNC2=C1C=CC=C2Cl IQYUCUOHMQQYTE-UHFFFAOYSA-N 0.000 claims 1
- PMQYJPDGLJMASA-UHFFFAOYSA-N 6-[4-(7-chloro-1h-indol-3-yl)piperidin-1-yl]-1-(3,4-dihydro-2h-quinolin-1-yl)hexan-1-one Chemical compound C1CCC2=CC=CC=C2N1C(=O)CCCCCN(CC1)CCC1C1=CNC2=C1C=CC=C2Cl PMQYJPDGLJMASA-UHFFFAOYSA-N 0.000 claims 1
- 229940005529 antipsychotics Drugs 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 81
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 66
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 63
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 60
- 239000000203 mixture Substances 0.000 description 57
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 42
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 36
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 28
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
- 229920005989 resin Polymers 0.000 description 23
- 239000011347 resin Substances 0.000 description 23
- 239000000243 solution Substances 0.000 description 23
- 238000000034 method Methods 0.000 description 22
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 21
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 20
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 18
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 18
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 18
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 18
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 18
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- 239000000741 silica gel Substances 0.000 description 16
- 229910002027 silica gel Inorganic materials 0.000 description 16
- 108090000357 Dopamine D4 receptors Proteins 0.000 description 15
- 102000003962 Dopamine D4 receptors Human genes 0.000 description 15
- 239000003480 eluent Substances 0.000 description 15
- 238000003818 flash chromatography Methods 0.000 description 15
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 239000003446 ligand Substances 0.000 description 12
- 230000029936 alkylation Effects 0.000 description 11
- 238000005804 alkylation reaction Methods 0.000 description 11
- -1 p-aminobenzo Chemical compound 0.000 description 11
- 239000005557 antagonist Substances 0.000 description 10
- 239000012043 crude product Substances 0.000 description 10
- 229960003638 dopamine Drugs 0.000 description 9
- 239000012074 organic phase Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 8
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 239000012267 brine Substances 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
- 108010072564 5-HT2A Serotonin Receptor Proteins 0.000 description 7
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 description 7
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 description 7
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 7
- 230000000561 anti-psychotic effect Effects 0.000 description 7
- 239000008346 aqueous phase Substances 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 238000006722 reduction reaction Methods 0.000 description 7
- VQFAITGIMWXQQK-UHFFFAOYSA-N 5-fluoro-3-piperidin-4-yl-1h-indole Chemical compound C12=CC(F)=CC=C2NC=C1C1CCNCC1 VQFAITGIMWXQQK-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 101150049660 DRD2 gene Proteins 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- 239000012458 free base Substances 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 102000004073 Dopamine D3 Receptors Human genes 0.000 description 5
- 108090000525 Dopamine D3 Receptors Proteins 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 4
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 4
- 108091005479 5-HT2 receptors Proteins 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 229910000086 alane Inorganic materials 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 4
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 4
- 230000003042 antagnostic effect Effects 0.000 description 4
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 230000007278 cognition impairment Effects 0.000 description 4
- 230000002301 combined effect Effects 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N monoethanolamine hydrochloride Natural products NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- ULTHEAFYOOPTTB-UHFFFAOYSA-N 1,4-dibromobutane Chemical compound BrCCCCBr ULTHEAFYOOPTTB-UHFFFAOYSA-N 0.000 description 3
- TZOYXRMEFDYWDQ-UHFFFAOYSA-N 3,4-dihydro-1h-quinolin-2-one Chemical compound C1=CC=C2NC(=O)CCC2=C1 TZOYXRMEFDYWDQ-UHFFFAOYSA-N 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 description 3
- 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 description 3
- WQKHERPPDYPMNX-UHFFFAOYSA-N 6-chloro-3,4-dihydro-2h-naphthalen-1-one Chemical compound O=C1CCCC2=CC(Cl)=CC=C21 WQKHERPPDYPMNX-UHFFFAOYSA-N 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 3
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 3
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 150000003891 oxalate salts Chemical class 0.000 description 3
- 239000004031 partial agonist Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000002464 receptor antagonist Substances 0.000 description 3
- 229940044551 receptor antagonist Drugs 0.000 description 3
- 238000005932 reductive alkylation reaction Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000000698 schizophrenic effect Effects 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- MZLUUIRCZKORFY-UHFFFAOYSA-N 1-(3-bromopropyl)-3,4-dihydroquinolin-2-one Chemical compound C1=CC=C2N(CCCBr)C(=O)CCC2=C1 MZLUUIRCZKORFY-UHFFFAOYSA-N 0.000 description 2
- SBLVUTXZGVPJNG-UHFFFAOYSA-N 1-(5-bromopentyl)-3,4-dihydroquinolin-2-one Chemical compound C1=CC=C2N(CCCCCBr)C(=O)CCC2=C1 SBLVUTXZGVPJNG-UHFFFAOYSA-N 0.000 description 2
- NKMQXCKKINTYTE-UHFFFAOYSA-N 2-(3-hydroxypropyl)-3,4-dihydroisoquinolin-1-one Chemical compound C1=CC=C2C(=O)N(CCCO)CCC2=C1 NKMQXCKKINTYTE-UHFFFAOYSA-N 0.000 description 2
- PYXROWKPLUHPEO-UHFFFAOYSA-N 2-(4-bromobutyl)-3,4-dihydroisoquinolin-1-one Chemical compound C1=CC=C2C(=O)N(CCCCBr)CCC2=C1 PYXROWKPLUHPEO-UHFFFAOYSA-N 0.000 description 2
- YWPMKTWUFVOFPL-UHFFFAOYSA-N 3,4-dihydro-2h-isoquinolin-1-one Chemical compound C1=CC=C2C(=O)NCCC2=C1 YWPMKTWUFVOFPL-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- OHNCEVGJAXRYEK-UHFFFAOYSA-N 4-chloro-1-(3,4-dihydro-1h-isoquinolin-2-yl)butan-1-one Chemical compound C1=CC=C2CN(C(=O)CCCCl)CCC2=C1 OHNCEVGJAXRYEK-UHFFFAOYSA-N 0.000 description 2
- CDIIZULDSLKBKV-UHFFFAOYSA-N 4-chlorobutanoyl chloride Chemical compound ClCCCC(Cl)=O CDIIZULDSLKBKV-UHFFFAOYSA-N 0.000 description 2
- CYQAPXIAEFXKPZ-UHFFFAOYSA-N 7-chloro-3-piperidin-4-yl-1h-indole Chemical compound C=1NC=2C(Cl)=CC=CC=2C=1C1CCNCC1 CYQAPXIAEFXKPZ-UHFFFAOYSA-N 0.000 description 2
- 206010001488 Aggression Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 2
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 208000012761 aggressive behavior Diseases 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000002152 alkylating effect Effects 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 239000000010 aprotic solvent Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- PCDHSSHKDZYLLI-UHFFFAOYSA-N butan-1-one Chemical compound CCC[C]=O PCDHSSHKDZYLLI-UHFFFAOYSA-N 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 229960004170 clozapine Drugs 0.000 description 2
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000003001 depressive effect Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical class C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 2
- 230000002197 limbic effect Effects 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 239000003176 neuroleptic agent Substances 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- UFUASNAHBMBJIX-UHFFFAOYSA-N propan-1-one Chemical compound CC[C]=O UFUASNAHBMBJIX-UHFFFAOYSA-N 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229950001675 spiperone Drugs 0.000 description 2
- 210000003568 synaptosome Anatomy 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 1
- ATWLRNODAYAMQS-UHFFFAOYSA-N 1,1-dibromopropane Chemical compound CCC(Br)Br ATWLRNODAYAMQS-UHFFFAOYSA-N 0.000 description 1
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- IBODDUNKEPPBKW-UHFFFAOYSA-N 1,5-dibromopentane Chemical compound BrCCCCCBr IBODDUNKEPPBKW-UHFFFAOYSA-N 0.000 description 1
- MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 1
- WUKQSLPBSUSULJ-UHFFFAOYSA-N 2-(2-oxo-3,4-dihydroquinolin-1-yl)ethyl acetate Chemical compound C1=CC=C2N(CCOC(=O)C)C(=O)CCC2=C1 WUKQSLPBSUSULJ-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- VIRWKAJWTKAIMA-UHFFFAOYSA-N 2-chloroethyl acetate Chemical compound CC(=O)OCCCl VIRWKAJWTKAIMA-UHFFFAOYSA-N 0.000 description 1
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 1
- YMMHAIJRFWRDMG-UHFFFAOYSA-N 3,4,4a,5-tetrahydro-1h-quinolin-2-one Chemical class C1C=CC=C2NC(=O)CCC21 YMMHAIJRFWRDMG-UHFFFAOYSA-N 0.000 description 1
- NTNKZGHUNBWBBV-UHFFFAOYSA-N 3,4,4a,5-tetrahydro-2h-isoquinolin-1-one Chemical class C1C=CC=C2C(=O)NCCC21 NTNKZGHUNBWBBV-UHFFFAOYSA-N 0.000 description 1
- CIRSPTXGPFAXRE-UHFFFAOYSA-N 3-(1,2,3,6-tetrahydropyridin-4-yl)-1h-indole Chemical class C1NCCC(C=2C3=CC=CC=C3NC=2)=C1 CIRSPTXGPFAXRE-UHFFFAOYSA-N 0.000 description 1
- RQFUZUMFPRMVDX-UHFFFAOYSA-N 3-Bromo-1-propanol Chemical compound OCCCBr RQFUZUMFPRMVDX-UHFFFAOYSA-N 0.000 description 1
- KWDNEXYJQKCUAP-UHFFFAOYSA-N 3-bromo-1-(3,4-dihydro-1h-isoquinolin-2-yl)propan-1-one Chemical compound C1=CC=C2CN(C(=O)CCBr)CCC2=C1 KWDNEXYJQKCUAP-UHFFFAOYSA-N 0.000 description 1
- IHBVNSPHKMCPST-UHFFFAOYSA-N 3-bromopropanoyl chloride Chemical compound ClC(=O)CCBr IHBVNSPHKMCPST-UHFFFAOYSA-N 0.000 description 1
- INUNLMUAPJVRME-UHFFFAOYSA-N 3-chloropropanoyl chloride Chemical compound ClCCC(Cl)=O INUNLMUAPJVRME-UHFFFAOYSA-N 0.000 description 1
- KAIRZPVWWIMPFT-UHFFFAOYSA-N 3-piperidin-4-yl-1h-indole Chemical class C1CNCCC1C1=CNC2=CC=CC=C12 KAIRZPVWWIMPFT-UHFFFAOYSA-N 0.000 description 1
- WXBFAQPNLNYCHD-UHFFFAOYSA-N 4-chloro-3-piperidin-4-yl-1h-indole Chemical compound C1=2C(Cl)=CC=CC=2NC=C1C1CCNCC1 WXBFAQPNLNYCHD-UHFFFAOYSA-N 0.000 description 1
- MVDXZCKFTCOBAO-UHFFFAOYSA-N 5-chloro-3-piperidin-4-yl-1h-indole Chemical compound C12=CC(Cl)=CC=C2NC=C1C1CCNCC1 MVDXZCKFTCOBAO-UHFFFAOYSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- OOCTTYYQKJICTN-UHFFFAOYSA-N 6-[4-(4-fluoro-1h-indol-3-yl)piperidin-1-yl]hexanoic acid Chemical compound C1CN(CCCCCC(=O)O)CCC1C1=CNC2=CC=CC(F)=C12 OOCTTYYQKJICTN-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- SKTFQHRVFFOHTQ-UHFFFAOYSA-N 8-bromo-1,3-dimethyl-7h-purine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Br)=N2 SKTFQHRVFFOHTQ-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 206010002869 Anxiety symptoms Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 238000003650 Calcium Assay Kit Methods 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- JGDTWLJIIATFOL-UHFFFAOYSA-N FC=1C=C2C(=CNC2=CC1)C1CCN(CC1)CCC(=O)O.FC1=C2C(=CNC2=CC=C1)C1CCN(CC1)CCC(=O)O.ClC1=C2C(=CNC2=CC=C1)C1CCN(CC1)CCC(=O)O Chemical compound FC=1C=C2C(=CNC2=CC1)C1CCN(CC1)CCC(=O)O.FC1=C2C(=CNC2=CC=C1)C1CCN(CC1)CCC(=O)O.ClC1=C2C(=CNC2=CC=C1)C1CCN(CC1)CCC(=O)O JGDTWLJIIATFOL-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101150104779 HTR2A gene Proteins 0.000 description 1
- 101000865206 Homo sapiens D(4) dopamine receptor Proteins 0.000 description 1
- 238000003109 Karl Fischer titration Methods 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000220225 Malus Species 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-L Oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 208000020114 Schizophrenia and other psychotic disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Natural products O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
- 239000003875 Wang resin Substances 0.000 description 1
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002539 anti-aggressive effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229940127236 atypical antipsychotics Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- OFJLSOXXIMLDDL-UHFFFAOYSA-N ethyl (4-nitrophenyl) carbonate Chemical compound CCOC(=O)OC1=CC=C([N+]([O-])=O)C=C1 OFJLSOXXIMLDDL-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000005558 fluorometry Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960005417 ketanserin Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000001690 micro-dialysis Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000001009 nucleus accumben Anatomy 0.000 description 1
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- UWBHMRBRLOJJAA-UHFFFAOYSA-N oxaluric acid Chemical compound NC(=O)NC(=O)C(O)=O UWBHMRBRLOJJAA-UHFFFAOYSA-N 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 210000002442 prefrontal cortex Anatomy 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- JZWFDVDETGFGFC-UHFFFAOYSA-N salacetamide Chemical group CC(=O)NC(=O)C1=CC=CC=C1O JZWFDVDETGFGFC-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- KVSNUBKMSMRZEV-UHFFFAOYSA-N tert-butyl 4-(7-chloro-1h-indol-3-yl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=CNC2=C(Cl)C=CC=C12 KVSNUBKMSMRZEV-UHFFFAOYSA-N 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200000919 | 2000-06-14 | ||
| US21244500P | 2000-06-16 | 2000-06-16 | |
| PCT/DK2001/000406 WO2001096328A1 (en) | 2000-06-14 | 2001-06-13 | Indole derivatives useful for the treatment of cns disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20026005D0 NO20026005D0 (no) | 2002-12-13 |
| NO20026005L NO20026005L (no) | 2002-12-13 |
| NO323236B1 true NO323236B1 (no) | 2007-02-05 |
Family
ID=26068835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20026005A NO323236B1 (no) | 2000-06-14 | 2002-12-13 | Indolderivater, deres anvendelse og farmasoytiske sammensetninger omfattende disse |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US6890916B2 (de) |
| EP (1) | EP1294710B1 (de) |
| JP (1) | JP2004503550A (de) |
| KR (1) | KR20030007967A (de) |
| AR (1) | AR028685A1 (de) |
| AT (2) | ATE297391T1 (de) |
| AU (2) | AU7388101A (de) |
| BG (1) | BG107449A (de) |
| CA (1) | CA2411412C (de) |
| CZ (1) | CZ200335A3 (de) |
| DE (2) | DE60130691T2 (de) |
| DK (1) | DK1468996T3 (de) |
| ES (2) | ES2290587T3 (de) |
| HR (1) | HRP20021008A2 (de) |
| HU (1) | HUP0301735A2 (de) |
| NO (1) | NO323236B1 (de) |
| NZ (1) | NZ523076A (de) |
| PT (2) | PT1468996E (de) |
| SG (1) | SG148840A1 (de) |
| WO (1) | WO2001096328A1 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2165274B1 (es) * | 1999-06-04 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de indolilpiperidina como agentes antihistaminicos y antialergicos. |
| EP1468996B1 (de) * | 2000-06-14 | 2007-09-26 | H. Lundbeck A/S | Indolderivate zur Behandlung von Erkrankungen des Zentralnervensystems |
| ES2172436B1 (es) | 2000-10-31 | 2004-01-16 | Almirall Prodesfarma Sa | Derivados de indolilpiperidina como agentes antihistaminicos y antialergicos. |
| WO2003102097A1 (en) * | 2002-05-31 | 2003-12-11 | H. Lundbeck A/S | The hydrochloride of (s)-(+)-3-[1-[2-(1-acetyl-2,3-dihydro-1h-indol-3-yl)ethyl]-1,2,3,6-tetrahydropyridin-4-yl]-6-chloro-1h-indole |
| WO2004020437A1 (en) * | 2002-08-29 | 2004-03-11 | H. Lundbeck A/S | S-(+)-3-{1-[2-(2,3-dihydro-1h-indol-3-yl)ethyl]-3,6-dihydro-2h-pyridin-4-yl}-6-chloro-1h-indole and acid addition salts thereof |
| GB0306604D0 (en) * | 2003-03-21 | 2003-04-30 | Curidium Ltd | Second medical use |
| WO2004108671A1 (en) * | 2003-06-06 | 2004-12-16 | Suven Life Sciences Limited | Substituted indoles with serotonin receptor affinity, process for their preparation and pharmaceutical compositions containing them |
| GB0708186D0 (en) * | 2007-04-27 | 2007-06-06 | Merck Sharp & Dohme | Therapeutic compounds |
| SE531698C2 (sv) | 2007-07-12 | 2009-07-07 | Respiratorius Ab | Nya bronkdilaterande a,b-omättade amider |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9202915D0 (en) * | 1992-02-12 | 1992-03-25 | Wellcome Found | Chemical compounds |
| ZA9711376B (en) * | 1996-12-20 | 1998-07-21 | Lundbeck & Co As H | Indole or dihydroindole derivatives |
| WO1999010346A1 (en) * | 1997-08-22 | 1999-03-04 | Eli Lilly And Company Limited | Benzothiadiazinyl-indole derivatives and their use as serotonin receptor ligands |
| GB9718833D0 (en) * | 1997-09-04 | 1997-11-12 | Merck Sharp & Dohme | Therapeutic agents |
| GB9810886D0 (en) * | 1998-05-13 | 1998-07-22 | Lilly Industries Ltd | Pharmaceutical compounds |
| GB9825413D0 (en) * | 1998-11-19 | 1999-01-13 | Lilly Co Eli | Pharmaceutical compounds |
| AU2494300A (en) * | 1999-01-07 | 2000-07-24 | American Home Products Corporation | 3,4-dihydro-2h-benzo(1,4)oxazine derivatives |
| EP1200072A2 (de) * | 1999-05-12 | 2002-05-02 | Solvay Pharmaceuticals B.V. | Verfahren zur behandlung von psychotischen erkrankungen |
| CN1158258C (zh) * | 1999-06-24 | 2004-07-21 | 东丽株式会社 | 肾上腺素能α1B受体拮抗药 |
| GB2362381A (en) * | 2000-05-18 | 2001-11-21 | Lilly Co Eli | Pharmaceutically active indolyl-piperidines |
-
2001
- 2001-06-06 AR ARP010102697A patent/AR028685A1/es not_active Application Discontinuation
- 2001-06-13 EP EP01940240A patent/EP1294710B1/de not_active Expired - Lifetime
- 2001-06-13 AU AU7388101A patent/AU7388101A/xx active Pending
- 2001-06-13 CZ CZ200335A patent/CZ200335A3/cs unknown
- 2001-06-13 KR KR1020027017034A patent/KR20030007967A/ko active IP Right Grant
- 2001-06-13 PT PT04012325T patent/PT1468996E/pt unknown
- 2001-06-13 AT AT01940240T patent/ATE297391T1/de not_active IP Right Cessation
- 2001-06-13 ES ES04012325T patent/ES2290587T3/es not_active Expired - Lifetime
- 2001-06-13 AT AT04012325T patent/ATE374197T1/de not_active IP Right Cessation
- 2001-06-13 DE DE60130691T patent/DE60130691T2/de not_active Expired - Fee Related
- 2001-06-13 DE DE60111379T patent/DE60111379T2/de not_active Expired - Fee Related
- 2001-06-13 CA CA002411412A patent/CA2411412C/en not_active Expired - Fee Related
- 2001-06-13 JP JP2002510470A patent/JP2004503550A/ja active Pending
- 2001-06-13 PT PT01940240T patent/PT1294710E/pt unknown
- 2001-06-13 AU AU2001273881A patent/AU2001273881B8/en not_active Ceased
- 2001-06-13 NZ NZ523076A patent/NZ523076A/en unknown
- 2001-06-13 HU HU0301735A patent/HUP0301735A2/hu unknown
- 2001-06-13 SG SG200501564-9A patent/SG148840A1/en unknown
- 2001-06-13 ES ES01940240T patent/ES2243508T3/es not_active Expired - Lifetime
- 2001-06-13 WO PCT/DK2001/000406 patent/WO2001096328A1/en active IP Right Grant
- 2001-06-13 DK DK04012325T patent/DK1468996T3/da active
-
2002
- 2002-12-09 US US10/315,927 patent/US6890916B2/en not_active Expired - Fee Related
- 2002-12-13 NO NO20026005A patent/NO323236B1/no unknown
- 2002-12-17 HR HR20021008A patent/HRP20021008A2/hr not_active Application Discontinuation
-
2003
- 2003-01-08 BG BG107449A patent/BG107449A/bg unknown
-
2005
- 2005-03-03 US US11/073,497 patent/US7276508B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7223765B2 (en) | 4-phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives | |
| US7276508B2 (en) | Indole derivatives useful for the treatment of CNS disorders | |
| NO20032636L (no) | 3-indolinderivater som er nyttige i behandlingen av psykiatriske og nevrologiske forstyrrelser | |
| AU2001273881A1 (en) | Indole derivatives useful for the treatment of CNS disorders | |
| EP1299380B1 (de) | Indolderivate zum gebrauch in der behandlung von zns-störungen | |
| NO323799B1 (no) | Indolderivater, farmasoytisk sammensetning inneholdende dem og deres anvendelse. | |
| EP1468996B1 (de) | Indolderivate zur Behandlung von Erkrankungen des Zentralnervensystems | |
| MXPA02012568A (es) | Derivados de indol utiles para el tratameinto de enfermedades del sistema nervioso central. | |
| MXPA02012149A (en) | Indole derivatives useful for the treatment of cns disorders | |
| IL153234A (en) | Indole derivatives and pharmaceutical compositions containing them for the treatment of cns disorders | |
| SK512003A3 (en) | Indole derivatives useful for the treatment of CNS disorders |